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Profile of Xiyun Yan 
 
Dr. Xiyun Yan obtained her B.S. degree in 1983, from the 
Henan Medical College, and then studied cell biology in 
Professor Shizhang Bei’s lab in the Institute of Biophysics, 
Chinese Academy of Sciences (CAS) until leaving for 
Germany in 1989. After receiving her medical doctor's de-
gree from Heidelberg University in Germany, she joined the 
Memorial Sloan-Kettering Institute in New York as a post-
doctoral research fellow. In 1997, Dr. Yan returned to China 
through her selection in the “Hundred Talents Program” by 
CAS. She has since studied tumor biology, finding novel 
targets and developing new methods for tumor diagnosis 
and therapy. Her work has been well recognized and re-
spected internationally through honors such as the National 
Prize for Natural Science and Atlas Award by Elsevier. In 
2015, she was elected as the new president of Asian Bio-
physics Association and Academician of Chinese Academy 
of Sciences.  
Dr. Yan’s scientific contributions in the emerging inter-
disciplinary field of biomedicine and nanotechnology are as 
follows: 
Nanozyme: Discovery and application in tumor 
diagnosis 
Dr. Yan’s research group observed that iron oxide nanopar-
ticles possessed peroxidase-like activity, which was the first 
report on intrinsic enzyme-like properties of nano-materials. 
She introduced the new concept of a nanozyme and was the 
first to use nano-materials as enzyme mimics to create new 
methods for tumor diagnosis and Nanozyme-strip for rapid 
local detection of infectious diseases like Ebola virus dis-
ease. This finding changed the general idea that nanoparti-
cles are chemically inert, and opened many new applica-
tions for nanoparticles in many important fields, including 
medicine, agriculture, food production, biotechnology, and 
environmental protection. Currently, nanozyme is consid-
ered as an emerging field that bridges biology and nano-
technology. 
CD146: Discovery and application in tumor 
immunotherapy  




target for tumor angiogenesis, identified the ligands of 
CD146, and developed therapeutic humanized antibodies 
for the treatment of liver cancer, pancreatic cancer, and co-
lon cancer. From discovery to preclinical studies, she has 
published more than 140 scientific papers, and the related 
patents have been licensed for $17 million USD. She has 
continuously focused on translating her findings into indus-
trial applications to improve human health and the envi-
ronment.   
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